Vaccines are a controversial topic these days. Research has pointed its finger at to vaccines as the cause of a variety of problems including autism. But immunotherapy, which involves the use of anti-cancer vaccines (or stem cells) to stimulate the body’s immune system, warrants a closer look in terms of cancer.
Immunotherapy uses vaccines or stem cells to stimulate the body’s immune system to kill cancer cells. Different vaccines work differently to kill cancer cells and it isn’t necessary for patients to fully understand the process to benefit from it. The immune system is complicated, after all. Pros of immunotherapy treatments include the following:
- When they work, immunotherapy treatments are powerful and effective.
- The treatments are quick and simple.
Cons of the immunotherapy is that it tends to be expensive and as a general rule, Americans must travel to a different country to get a cancer vaccine or they can take part in a clinical trial (which as a general rule is not recommended by this author unless a major change takes place in the United States health care system). Signing up for a clinical trial to be a guinea pig for a major university studying cancer vaccines means that you’ll be placed into either a “placebo/control” group or the “experimental” group. If you’re placed in the placebo group, you’ll receive no treatment at all, but you’ll think that you’re being treated. If you’re in the experimental group, you may not be fully informed about what treatment you’re receiving. Both are losing scenarios. At the end of the trial, if you survive, you’ll be recorded as nothing but a statistic. If you don’t survive, your death may not be recorded unless it benefits the study’s funding agents in some way to record it.
Dr. Livingston-Wheeler had one of the most advanced theories regarding the development of cancer and how to treat the disease. She developed a full protocol that included dietary recommendations along with a vaccine that targeted Progenitor cryptocides, a cancer-causing mycobacterium that she regarded as being closely related to the infectious agents that cause tuberculosis and leprosy. In reality, given that Livingston-Wheeler observed that P. crytocides was pleomorphic, P. crytocides was likely a somatid in one of its infectious forms. Her theories and protocol are supported by a variety of other cancer researchers from different eras working on different aspects of the disease, but despite this her work was easily tossed aside by the Medical Establishment in the U.S. and Big Pharma. She was one of few women working in the medical profession when she entered the field and her observations about the cancer mycobacterium P. cryptocides were novel and innovative. Her treatment is sadly all but extinct today.
RigVir, a cancer vaccine that was developed in Riga, Latvia, is a powerful anti-cancer treatment that can also be used to prevent cancer. Few Americans know about it because the FDA has not approved it even though it’s used in a number of countries in Europe. While other extremely promising cancer treatments have languished over the years, the development and propagation of RigVir in Europe appears to be tied to its high cost, or rather, the fact that the European medical industry is able to charge a relatively high price for it. But the cost of RigVir depends on where patients go to get it. It is much cheaper to get RigVir treatments in Latvia than it is to get it in Tijuana, Mexico, for example. Expense is a major factor that limits patients’ accessibility to this treatment modality, which is perhaps why it’s production and distribution hasn’t been squelched yet by the Powers That Be. Cancer vaccines that have been developed to compete with RigVir for use in the United States have so far only made use of dangerous viruses that can cause undesirable side effects in patients. By law, the pharmaceutical companies in the U.S. must develop a vaccine made of a substance that is modified and therefore able to be patented (otherwise it won’t be profitable). Because of the law that requires all drugs to be patentable, non-natural, synthetic substances are part of what maintain the monopoly that large pharmaceutical companies have over the American healthcare system. RigVir is made from a non-modified ECHO-7 virus that exists naturally in the human colon. It was developed and researched in Latvia and Russia between 1968 and 1991 under a different political regime.
Latvians are reimbursed for RigVir treatments used for melanoma. In other words, they receive the treatment for free. In 2008, the International Virotherapy Center was established in Latvia with the mission to provide virotherapy information to every cancer patient who wants it.